Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc.（AVTE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · AVTE · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
64
近12个月
买卖比
0.02
Buy/Sell (by trades)
整体情绪
Aerovate Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
AVTE 季度内部人买卖趋势
AVTE 内幕交易卖出 · AVTE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
AVTE 高管卖出股份 · AVTE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Aug 1, 2024 | Dake Benjamin T SEE REMARKS | Option | 1,507 | $3K | Form 4 |
| Jul 31, 2024 | Dake Benjamin T SEE REMARKS | Option | 11,454 | $20K | Form 4 |
| Jun 17, 2024 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 928,110 | $1.55M⚡ | Form 4 |
| Jun 14, 2024 | Eldridge George A SEE REMARKS | Option | 15,000 | $32K | Form 4 |
| Jun 14, 2024 | Eldridge George A SEE REMARKS | Sale | 15,000 | $375K | Form 4 |
| Jun 14, 2024 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Option | 10,600 | $155K | Form 4 |
| Jun 14, 2024 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale | 10,600 | $265K | Form 4 |
| Jun 13, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Option | 6,000 | $13K | Form 4 |
| Jun 13, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale | 6,000 | $147K | Form 4 |
| May 17, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Option | 4,000 | $9K | Form 4 |
| May 17, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale | 3,914 | $82K | Form 4 |
| May 17, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale | 86 | $2K | Form 4 |
| May 16, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Option | 10,000 | $21K | Form 4 |
| May 16, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Sale | 8,707 | $187K | Form 4 |
| May 16, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Sale | 1,293 | $28K | Form 4 |
| May 2, 2024 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale | 1,981 | $42K | Form 4 |
| May 1, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Option | 10,000 | $21K | Form 4 |
| May 1, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Sale | 9,035 | $184K | Form 4 |
| May 1, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Sale | 1,357 | $27K | Form 4 |
| May 1, 2024 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director | Sale | 965 | $20K | Form 4 |
| Apr 17, 2024 | Dake Benjamin T SEE REMARKS | Option | 6,853 | $15K | Form 4 |
| Apr 17, 2024 | Dake Benjamin T SEE REMARKS | Sale | 6,447 | $144K | Form 4 |
| Apr 17, 2024 | Dake Benjamin T SEE REMARKS | Sale | 338 | $8K | Form 4 |
| Apr 17, 2024 | Dake Benjamin T SEE REMARKS | Sale | 68 | $2K | Form 4 |
| Apr 17, 2024 | Gillies Hunter CHIEF MEDICAL OFFICER | Option | 4,000 | $7K | Form 4 |
RA CAPITAL MANAGEMENT, L.P.
Director
日期
Jun 17
股数
928,110
均价
$1.67
总金额
$1.55M ⚡
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 16
股数
10,000
均价
$2.14
总金额
$21K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 16
股数
8,707
均价
$21.52
总金额
$187K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 16
股数
1,293
均价
$21.92
总金额
$28K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 1
股数
10,000
均价
$2.14
总金额
$21K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 1
股数
9,035
均价
$20.34
总金额
$184K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 1
股数
1,357
均价
$19.91
总金额
$27K
NOYES TIMOTHY P
CHIEF EXECUTIVE OFFICER · Director
日期
May 1
股数
965
均价
$20.87
总金额
$20K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 AVTE 内幕交易
AVTE 内幕交易
Aerovate Therapeutics, Inc.（AVTE）内幕交易数据来源于公司内部人（包括AVTE）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。AVTE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Aerovate Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
AVTE 内幕交易 · 5个问题Aerovate Therapeutics, Inc.（AVTE）的内部人包括高管和董事，如AVTE等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026